Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Lebwohl

Showing results (291-300 of 418) with videos related to

Pageof 42
Sort By:
Journal of the American Academy of Dermatology|October 25, 2003
AAD consensus statement on psoriasis therapiesJeffrey P Callen, Gerald G Krueger, Mark Lebwohl, et al.
Journal of the American Academy of Dermatology|September 21, 2011
Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trialsMark Lebwohl, Craig Leonardi, Christopher E M Griffiths, et al.
Journal of the American Academy of Dermatology|November 4, 2004
Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized studyCarin Gribetz, Mark Ling, Mark Lebwohl, et al.
American Journal of Clinical Dermatology|September 30, 2018
Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Sanminder Singh, Robert E Kalb, Elke M G J de Jong, et al.
Journal of the American Academy of Dermatology|February 8, 2020
Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind studyAbby S Van Voorhees, Linda Stein Gold, Mark Lebwohl, et al.
Digestive Diseases and Sciences|May 29, 2024
The Burden of Work Productivity and Activity Impairment in Patients with Psoriasis, Psoriatic Arthritis, Ulcerative Colitis, and Crohn's DiseaseJud C Janak, Anita M Loughlin, Page C Moore, et al.
Journal of Cutaneous Medicine and Surgery|May 16, 2006
Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part IDavid M Pariser, Kenneth B Gordon, Kim A Papp, et al.
Journal of Drugs in Dermatology : JDD|August 7, 2025
Two-Year Treatment Persistence of Guselkumab vs Other Biologics in Plaque Psoriasis PatientsBruce E Strober, Jud C Janak, Timothy Fitzgerald, et al.
Acta Dermato-Venereologica|September 12, 2024
<u>N</u>otalgia <u>P</u>aresthetica <u>De</u>rmatologist <u>R</u>eport of Sy<u>m</u>ptom Burden and Treatment: Results from a Physician SurveyBrian S Kim, Sonja Ständer, Kenji Kabashima, et al.
The British Journal of Dermatology|November 11, 2023
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trialsKenneth B Gordon, Richard G Langley, Richard B Warren, et al.
Pageof 42

Showing results (291-300 of 418) with videos related to

Sort By:
Pageof 42
Journal of the American Academy of Dermatology|October 25, 2003
AAD consensus statement on psoriasis therapiesJeffrey P Callen, Gerald G Krueger, Mark Lebwohl, et al.
Journal of the American Academy of Dermatology|September 21, 2011
Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trialsMark Lebwohl, Craig Leonardi, Christopher E M Griffiths, et al.
Journal of the American Academy of Dermatology|November 4, 2004
Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized studyCarin Gribetz, Mark Ling, Mark Lebwohl, et al.
American Journal of Clinical Dermatology|September 30, 2018
Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Sanminder Singh, Robert E Kalb, Elke M G J de Jong, et al.
Journal of the American Academy of Dermatology|February 8, 2020
Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind studyAbby S Van Voorhees, Linda Stein Gold, Mark Lebwohl, et al.
Digestive Diseases and Sciences|May 29, 2024
The Burden of Work Productivity and Activity Impairment in Patients with Psoriasis, Psoriatic Arthritis, Ulcerative Colitis, and Crohn's DiseaseJud C Janak, Anita M Loughlin, Page C Moore, et al.
Journal of Cutaneous Medicine and Surgery|May 16, 2006
Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part IDavid M Pariser, Kenneth B Gordon, Kim A Papp, et al.
Journal of Drugs in Dermatology : JDD|August 7, 2025
Two-Year Treatment Persistence of Guselkumab vs Other Biologics in Plaque Psoriasis PatientsBruce E Strober, Jud C Janak, Timothy Fitzgerald, et al.
Acta Dermato-Venereologica|September 12, 2024
<u>N</u>otalgia <u>P</u>aresthetica <u>De</u>rmatologist <u>R</u>eport of Sy<u>m</u>ptom Burden and Treatment: Results from a Physician SurveyBrian S Kim, Sonja Ständer, Kenji Kabashima, et al.
The British Journal of Dermatology|November 11, 2023
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trialsKenneth B Gordon, Richard G Langley, Richard B Warren, et al.
Pageof 42